Zolmitriptan
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Zolmitriptan: From Migraine to Migraine with Brainstem Aura
One-Sentence Summary
Zolmitriptan is a selective 5-HT1B/1D receptor agonist (triptan) used globally for the acute treatment of migraine. The TxGNN model predicts it may be effective for Migraine with Brainstem Aura, but this indication carries a well-known drug-class safety concern that current evidence does not resolve — supporting literature covers general migraine/triptan use, with no clinical trials specifically on this aura subtype.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine, acute treatment (general population; formal Taiwan indication text unavailable — drug not licensed) |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 (Review/observational literature; no disease-specific RCTs) |
| US Market Status | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed formal mechanism-of-action data for zolmitriptan is not available in this evidence pack (data gap). Based on the supporting literature, zolmitriptan is known to be a selective serotonin 5-HT1B/1D receptor agonist that constricts intracranial (extracerebral) blood vessels and inhibits neuropeptide release from the trigeminovascular system — the standard mechanism underlying triptan efficacy in typical migraine, with or without aura.
However, “migraine with brainstem aura” (formerly known as basilar-type or basilar migraine) is a distinct clinical entity involving posterior (vertebrobasilar) circulation symptoms. Because triptans theoretically cause vasoconstriction, this subtype has traditionally been treated as a relative contraindication for the triptan class in several international guidelines (including AHS/AAN), out of concern for exacerbating posterior-circulation ischemia. None of the 19 supporting publications specifically evaluate zolmitriptan’s safety or efficacy in this aura subtype with controlled data — they largely address migraine in general or migraine with typical aura.
TxGNN’s high prediction score (99.99%) most likely reflects zolmitriptan’s strong association with the broader “migraine” disease node rather than validated applicability to this specific, mechanistically sensitive subtype. This is a case where the model’s output should be interpreted with caution rather than as straightforward evidence of a novel, safe indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11903526 | 2001 | Report | Headache | Directly addresses triptan use in basilar migraine and migraine with prolonged aura — the most topic-relevant reference, but reports clinical experience rather than controlled trial data. |
| 25916333 | 2015 | Review/Meta-analysis | J Headache Pain | Compares frovatriptan vs. rizatriptan/zolmitriptan/almotriptan specifically in migraine with aura; notes triptans are generally not effective when taken during the aura phase itself. |
| 22644173 | 2012 | RCT (subgroup analysis) | Neurol Sci | Double-blind, randomized, multicenter Italian study; subgroup of 18 patients with migraine with aura compared frovatriptan vs. zolmitriptan 2.5 mg. |
| 18624801 | 2008 | RCT | Cephalalgia | Randomized trial across six triptans in migraine patients with/without aura and early allodynia; examined differential pain-reduction response. |
| 15581383 | 2004 | RCT | CNS Drugs | Zolmitriptan 5 mg orally disintegrating tablet showed rapid onset of headache response in acute migraine (general population, not aura-subtype specific). |
| 27329280 | 2016 | RCT (TEENZ study) | Headache | Randomized, double-blind, multicenter trial (NCT01211145) of zolmitriptan nasal spray in adolescents (12–17y) for acute migraine; pain-free at 2h as primary endpoint. |
| 25600718 | 2015 | Review/Guideline | Headache | AHS evidence assessment of acute migraine pharmacotherapies; establishes zolmitriptan’s evidence tier for general migraine, not brainstem-aura subtype. |
| 9399016 | 1997 | Cohort (safety) | Cephalalgia | Large tolerability dataset (>3,000 subjects, ~50,000 doses) for zolmitriptan; establishes general adverse event profile. |
| 12083998 | 2002 | Review | Expert Opin Pharmacother | General review of zolmitriptan pharmacology and clinical applications in migraine. |
| 10473025 | 1999 | Review | Drugs | Comprehensive review of zolmitriptan’s efficacy/tolerability across RCTs in general migraine populations. |
US Market Information
Zolmitriptan currently has no market authorization records in this jurisdiction — market status is Not Marketed with 0 licenses on file. No dosage form, brand name, or approved-indication data is available to report.
Safety Considerations
Please refer to the package insert for safety information (TFDA warning/contraindication data and DDI data are currently unavailable — see data gap DG001, marked as Blocking for safety assessment).
Known drug-class caution (from mechanistic literature, not formal label data): Triptans, including zolmitriptan, are conventionally treated as a relative contraindication in migraine with brainstem (basilar-type) aura due to theoretical vasoconstrictive risk in the posterior circulation. This should be treated as a priority safety question pending formal label review, not as a resolved issue.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is not supported by disease-specific clinical evidence, and the underlying pharmacology raises a recognized safety concern (relative contraindication of triptans in brainstem-aura migraine) that current data cannot resolve. Formal TFDA safety labeling data is also blocked (DG001), preventing even an initial (S1) safety screen.
To proceed, the following is needed:
- TFDA/international package insert warnings and contraindications specific to zolmitriptan (resolve DG001)
- Confirmed formal mechanism-of-action documentation from DrugBank (resolve DG002)
- Any case series, pharmacovigilance data, or controlled studies specifically evaluating triptan safety in migraine with brainstem aura
- Expert neurology/headache-specialist review of the vasoconstriction risk-benefit before any further advancement
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.